Progress with interferon in CML--results of the MRC UK CML III study.
527 patients with CML were entered into the multicentre randomised MRC CML III study comparing IFN-alpha n1 to standard chemotherapy, either busulphan or hydroxyurea. Haematologic response to IFN as assessed by the level of control of the WCC predicted cytogenetic response to IFN. Cytogenetic respon...
| Main Authors: | , , |
|---|---|
| Format: | Conference item |
| Published: |
1996
|
| _version_ | 1797057452379734016 |
|---|---|
| author | Shepherd, P Richards, S Allan, N |
| author_facet | Shepherd, P Richards, S Allan, N |
| author_sort | Shepherd, P |
| collection | OXFORD |
| description | 527 patients with CML were entered into the multicentre randomised MRC CML III study comparing IFN-alpha n1 to standard chemotherapy, either busulphan or hydroxyurea. Haematologic response to IFN as assessed by the level of control of the WCC predicted cytogenetic response to IFN. Cytogenetic response (< 80% Ph + ve) was seen in 22% of all patients randomised, 11% showing major or complete responses. Major cytogenetic response rate was 18% in Sokal low risk patients, 15% in intermediate risk patients but only 4% in high risk patients. Mantel Byar analyses allowing for time to response showed a survival advantage for cytogenetic responders compared to non-responders. In addition, cytogenetic non-responders to IFN did significantly better than chemotherapy-treated patients. Median survival for all patients was 61 months in the IFN treated groups and 41 months in the no-IFN group. For Ph + ve patients only, the median survival was 63 months compared to 43 months. Sub-group analysis comparing busulphan or hydroxyurea treatment in the IFN and no-IFN treatment arms showed a significant advantage for IFN-compared to busulphan, but no significant difference between IFN and hydroxyurea treated patients, although there was a trend favouring IFN. A proposed overview of all randomised trials comparing IFN to hydroxyurea should, by virture of larger numbers, enable a more accurate assessment of the probable benefit of IFN compared to hydroxyurea therapy. |
| first_indexed | 2024-03-06T19:36:33Z |
| format | Conference item |
| id | oxford-uuid:1f405193-0314-44da-bdd0-d34d70ec162c |
| institution | University of Oxford |
| last_indexed | 2024-03-06T19:36:33Z |
| publishDate | 1996 |
| record_format | dspace |
| spelling | oxford-uuid:1f405193-0314-44da-bdd0-d34d70ec162c2022-03-26T11:20:46ZProgress with interferon in CML--results of the MRC UK CML III study.Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:1f405193-0314-44da-bdd0-d34d70ec162cSymplectic Elements at Oxford1996Shepherd, PRichards, SAllan, N527 patients with CML were entered into the multicentre randomised MRC CML III study comparing IFN-alpha n1 to standard chemotherapy, either busulphan or hydroxyurea. Haematologic response to IFN as assessed by the level of control of the WCC predicted cytogenetic response to IFN. Cytogenetic response (< 80% Ph + ve) was seen in 22% of all patients randomised, 11% showing major or complete responses. Major cytogenetic response rate was 18% in Sokal low risk patients, 15% in intermediate risk patients but only 4% in high risk patients. Mantel Byar analyses allowing for time to response showed a survival advantage for cytogenetic responders compared to non-responders. In addition, cytogenetic non-responders to IFN did significantly better than chemotherapy-treated patients. Median survival for all patients was 61 months in the IFN treated groups and 41 months in the no-IFN group. For Ph + ve patients only, the median survival was 63 months compared to 43 months. Sub-group analysis comparing busulphan or hydroxyurea treatment in the IFN and no-IFN treatment arms showed a significant advantage for IFN-compared to busulphan, but no significant difference between IFN and hydroxyurea treated patients, although there was a trend favouring IFN. A proposed overview of all randomised trials comparing IFN to hydroxyurea should, by virture of larger numbers, enable a more accurate assessment of the probable benefit of IFN compared to hydroxyurea therapy. |
| spellingShingle | Shepherd, P Richards, S Allan, N Progress with interferon in CML--results of the MRC UK CML III study. |
| title | Progress with interferon in CML--results of the MRC UK CML III study. |
| title_full | Progress with interferon in CML--results of the MRC UK CML III study. |
| title_fullStr | Progress with interferon in CML--results of the MRC UK CML III study. |
| title_full_unstemmed | Progress with interferon in CML--results of the MRC UK CML III study. |
| title_short | Progress with interferon in CML--results of the MRC UK CML III study. |
| title_sort | progress with interferon in cml results of the mrc uk cml iii study |
| work_keys_str_mv | AT shepherdp progresswithinterferonincmlresultsofthemrcukcmliiistudy AT richardss progresswithinterferonincmlresultsofthemrcukcmliiistudy AT allann progresswithinterferonincmlresultsofthemrcukcmliiistudy |